{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:18:46Z","timestamp":1783426726300,"version":"3.54.6"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01466-3","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:54:50Z","timestamp":1754481290000},"page":"2911-2923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-3149","authenticated-orcid":false,"given":"Kate K.","family":"Orroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Cordey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-4520","authenticated-orcid":false,"given":"Shia T.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Deignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Jardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini K.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alan","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"1466_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"1466_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13555-023-00929-9","volume":"13","author":"JF Merola","year":"2023","unstructured":"Merola JF, Ogdie A, Gottlieb AB, et al. Patient and physician perceptions of psoriatic disease in the United States: results from the UPLIFT survey. Dermatol Ther (Heidelb). 2023;13:1329\u201346.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1466_CR3","first-page":"997","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997\u20131035.","journal-title":"Br J Dermatol"},{"key":"1466_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","volume":"239","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Bohannan B, Mburu S, et al. Patient perspectives on psoriatic disease burden: results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239:621\u201334.","journal-title":"Dermatology"},{"key":"1466_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","volume":"86","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L, Papp K, Leonardi C, et al. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022;86:77\u201385.","journal-title":"J Am Acad Dermatol"},{"key":"1466_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","volume":"60","author":"A Menter","year":"2009","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643\u201359.","journal-title":"J Am Acad Dermatol"},{"key":"1466_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1466_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82:117\u201322.","journal-title":"J Am Acad Dermatol"},{"key":"1466_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13555-023-01065-0","volume":"14","author":"ME Horner","year":"2024","unstructured":"Horner ME, Orroth KK, Ma J, Duan Y, Cordey M. Redefining disease severity with special area involvement and reflecting on treatment patterns in a real-world psoriasis population. Dermatol Ther (Heidelb). 2024;14:187\u201399.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1466_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.25251\/skin.8.1.2","volume":"8","author":"M Shah","year":"2024","unstructured":"Shah M, Miller L, Casquejo R, et al. Topical cycling: the obstacles to moving forward with systemic psoriasis therapies and how to characterize the systemic ready patient. SKIN J Cutan Med. 2024;8:1217\u201331.","journal-title":"SKIN J Cutan Med"},{"key":"1466_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"AB Kimball","year":"2010","unstructured":"Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989\u20131004.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1466_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80:1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"key":"1466_CR13","unstructured":"Otezla [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2024."},{"key":"1466_CR14","unstructured":"Real-world data and AI for medical research and personalized medicine. 2024. Available at: https:\/\/www.om1.com\/. Accessed 24 Apr 2024."},{"key":"1466_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76:290\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1466_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/0962280210395740","volume":"22","author":"SR Seaman","year":"2013","unstructured":"Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22:278\u201395.","journal-title":"Stat Methods Med Res"},{"key":"1466_CR17","unstructured":"Brookhart M, Breskin A, Eledath B. causalRisk: Tools for estimating and plotting cumulative risk functions. R package version 0.40.2. Target PharmaSolutions, Inc.; 2024."},{"key":"1466_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatol Ther (Heidelb). 2022;12:61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1466_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","volume":"83","author":"AS Van Voorhees","year":"2020","unstructured":"Van Voorhees AS, Gold LS, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020;83:96\u2013103.","journal-title":"J Am Acad Dermatol"},{"key":"1466_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/jdv.18689","volume":"37","author":"U Mrowietz","year":"2023","unstructured":"Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas, and impaired quality of life: results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37:348\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1466_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","volume":"90","author":"JF Merola","year":"2024","unstructured":"Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90:485\u201393.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01466-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01466-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01466-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:06:16Z","timestamp":1758719176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01466-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01466-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April Armstrong: AbbVie, Almirall, Amgen, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, EPI Health, Incyte, LEO Pharma, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer\u2014research investigator and\/or scientific advisor. Bruce Strober: AbbVie, Almirall, Amgen, Arcutis Biotherapeutics, Arena, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Connect Biopharma, Dermavant, Dermira, Eli Lilly, Equillium, GlaxoSmithKline, Immunic Therapeutics, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, and UCB\u2014consultant (honoraria); AbbVie, Amgen, Eli Lilly, Janssen, Sanofi-Genzyme \u2013 speaker; CorEvitas\u2019 Psoriasis Registry \u2013 co-scientific director (consulting fee); AbbVie, Cara, CorEvitas\u2019 Psoriasis Registry, Dermavant, Dermira, and Novartis\u2014investigator; Journal of Psoriasis and Psoriatic Arthritis\u2014Editor-in-Chief (honorarium). Paolo Gisondi: AbbVie, Amgen, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB\u2014consultant and grant\/research support. Paolo Gisondi is an editorial board member of Dermatology and Therapy. Paolo Gisondi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kate K. Orroth: Amgen\u2014employment and stock ownership. Myriam Cordey: Amgen\u2014employment and stock ownership. Shia T. Kent: Amgen\u2014employment and stock ownership. Cynthia Deignan: Amgen\u2014employment and stock ownership. Shauna Jardon: Amgen\u2014employment and stock ownership at the time of analysis and manuscript development. Rohini K. Hernandez: Amgen\u2014employment and stock ownership. M. Alan Brookhart: Scientific advisory committees for American Academy of Allergy, Asthma & Immunology, Amgen, Atara Biotherapeutics, the Brigham and Women\u2019s Hospital, Gilead\/Kite, Intercept, National Institute of Diabetes and Digestive and Kidney Diseases, Regeneron, and Vertex; equity in Accompany Health and Target RWE. Linda Stein Gold: AbbVie, Amgen, Arcutis Biotherapeutics, Celgene Corporation, Dermira, Dermavant, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB, and Valeant\u2014honoraria, grants, and\/or research funding as a speaker, investigator, advisory board member.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval was not required for this analysis. All database records were deidentified and fully compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}